Cencora (MIL:1COR) ROCE %: 40.32% (As of Mar. 2026)


MIL:1COR Cencora Inc MIL:1COR
55 GF Score
Price €229.90
GF Value €233.91
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Cencora ROCE %?

Cencora MIL:1COR 55 ROCE % is 40.32% as of Mar. 2026. GuruFocus rates MIL:1COR with a GF Score™ of 55/100 and a GF Value™ of €233.91 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cencora's annualized ROCE % for the quarter that ended in Mar. 2026 was 40.32%.

Cencora  (MIL:1COR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cencora ROCE % Related Terms

Cencora ROCE % Historical Data

* Premium members only.

The historical data trend for Cencora's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cencora ROCE % Chart

Cencora Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.16 18.05 17.17 16.62 16.57

Cencora Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.81 20.75 -1.59 16.90 40.32
MIL:1COR
55GF Score
Cencora Inc MIL:1COR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cencora ROCE % Calculation

Cencora's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=2281.732/( ( (60458.602 - 48903.625) + (65254.775 - 49263.099) )/ 2 )
=2281.732/( (11554.977+15991.676)/ 2 )
=2281.732/13773.3265
=16.57 %

Cencora's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=7760.48/( ( (66920.477 - 50498.847) + (70629.066 - 48554.427) )/ 2 )
=7760.48/( ( 16421.63 + 22074.639 )/ 2 )
=7760.48/19248.1345
=40.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 40.32% mean?
Cencora (MIL:1COR) has a ROCE % of 40.32% as of Mar. 2026.
Is Cencora's ROCE % too high?
Cencora's current ROCE % is 40.32%. The Medical Distribution industry median ROCE % is 9.22. Cencora's value of 40.32% is 337.3% above this industry median. Overall, Cencora has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's ROCE % compare to CAH and MCK?
Cencora's ROCE % of 40.32% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.22. Cencora's value of 40.32% is 337.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.22, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current ROCE % of 40.32% is 337.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current ROCE % is 40.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (MIL:1COR) is currently considered Fairly Valued. The stock's GF Value™ is €233.91, compared to a current price of €229.90 — trading 1.7% below its estimated fair value. The current ROCE % is 40.32% and 337.3% above the Medical Distribution industry median of 9.22. Cencora's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cencora (MIL:1COR), the current ROCE % is 40.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cencora (MIL:1COR) Overvalued in 2026?

Based on GuruFocus' analysis, Cencora stock appears to be undervalued. The current stock price of €229.90 is trading 1.7% below its estimated GF Value™ of €233.91. GuruFocus considers Cencora to be Fairly Valued.

Key valuation signals for MIL:1COR:

  • ROCE %: 40.32%
  • GF Value™: €233.91 vs. price of €229.90 (1.7% below fair value)
  • GF Score™: 55/100 with 1 warning sign
  • Industry Position: 337.3% above the Medical Distribution median

No single metric tells the full story. See the MIL:1COR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cencora Business Description

Address 1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
55GF Score

Get the complete analysis for MIL:1COR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€229.90
Price
€233.91
GF Value